Clinical benefit of ixazomib plus lenalidomide‐dexamethasone in myeloma patients with non‐canonical NF‐κB pathway activation

c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma

(2020) Alessandra Di Bacco et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of nuclear factor κB pathways

(2019) Hiromi Muraoka et al.   CANCER SCIENCE

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

(2018) Neeraj Gupta et al.   CLINICAL PHARMACOKINETICS

Ixazomib for the treatment of multiple myeloma

(2018) Paul G. Richardson et al.   EXPERT OPINION ON PHARMACOTHERAPY

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

(2017) María-Victoria Mateos et al.   HAEMATOLOGICA

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients

(2017) V Shah et al.   LEUKEMIA

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

(2017) María-Victoria Mateos et al.   HAEMATOLOGICA

Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis

(2016) Amro M. S. El-Ghammaz et al.   ANNALS OF HEMATOLOGY

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

(2016) P. Sonneveld et al.   BLOOD

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Philippe Moreau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Non-canonical NFκB mutations reinforce pro-survival TNF response in multiple myeloma through an autoregulatory RelB:p50 NFκB pathway

(2016) P Roy et al.   ONCOGENE

Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2 - implications for a combinatorial treatment

(2015) Charlotte Fristedt Duvefelt et al.   Oncotarget

A critical role for the NFkB pathway in multiple myeloma

(2015)   Oncotarget

Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB

(2015) Yulia N. Demchenko et al.   Oncotarget

IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells

(2014) HIROMASA HIDESHIMA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Genome-Wide Screening of Cytogenetic Abnormalities in Multiple Myeloma Patients Using Array-CGH Technique: A Czech Multicenter Experience

(2014) Jan Smetana et al.   Biomed Research International

Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials

(2013) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

(2013) Kristian Cibulskis et al.   NATURE BIOTECHNOLOGY

OSA: a fast and accurate alignment tool for RNA-Seq

(2012) Jun Hu et al.   BIOINFORMATICS

Dual Inhibition of Canonical and Noncanonical NF- B Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma

(2012) C. Fabre et al.   CLINICAL CANCER RESEARCH

The noncanonical NF-κB pathway

(2012) Shao-Cong Sun   IMMUNOLOGICAL REVIEWS

RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome

(2011) Bo Li et al.   BMC BIOINFORMATICS

In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells

(2011) Dharminder Chauhan et al.   CLINICAL CANCER RESEARCH

Classical and/or alternative NF- B pathway activation in multiple myeloma

(2010) Y. N. Demchenko et al.   BLOOD

Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)

(2010) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells

(2009) T. Hideshima et al.   BLOOD